Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age

Tzou Yien Lin, Ying Hsiang Wang, Luan Yin Chang, Cheng Hsun Chiu, Yhu Chering Huang, Haiwen Tang, Hans L. Bock

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

Background: Combined vaccines are urgently needed to ensure compliance with the increasing number of recommended vaccines for children. We evaluated the safety and antibody response to a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b (DTaP-IPV/Hib) combination vaccine administrated to infants at 2, 4, and 6 months of age. Methods: Sixty healthy infants between 6 and 12 weeks of age were enrolled. One group of vaccines received the DTaP-IPV/Hib in a single injection, while another group concurrently received DTaP-IPV and Hib at separate injection sites. Solicited adverse events were monitored by parental observation and were recorded on a diary card. Levels of serum antibodies to DTaP and polyribosyl-ribitolphosphate-tetanus (PRP-T) antigens were collected before the first vaccine dose and 1 month after the third vaccine dose. Results: The combined-injection group tended to have lower local reactions, and there was no increase in reactogenicity when compared with the separate-injection group. Seroconversion rates were 100% in both groups for all antigens, except for the anti-polio 2 antibody in the combined-injection group (96.4%). The combined-injection group had lower antibody levels of PRP (8.45 μg/ml) than did the separate-injection group (20.61 μg/ml). However, the percentage of vaccines achieving protective levels of antibody to PRP (≥ 0.15 μg/ml or ≥ 1.0 μg/ml) was similar in both groups. Conclusions: DTaP-IPV/Hib may be safely and effectively administered to healthy infants, using a 2-, 4-, and 6-month vaccination schedule. This combined vaccine is cost-effective, more acceptable to parents and physicians, and minimizes distress to infants.
原文英語
頁(從 - 到)315-322
頁數8
期刊Chang Gung Medical Journal
26
發行號5
出版狀態已發佈 - 五月 1 2003
對外發佈Yes

指紋

Inactivated Poliovirus Vaccine
Combined Vaccines
Haemophilus influenzae type b
Diphtheria
Whooping Cough
Tetanus
Safety
Injections
Vaccines
Antibodies
Diphtheria-Tetanus-acellular Pertussis Vaccines
Antigens
Poliomyelitis
Antibody Formation
Appointments and Schedules
Vaccination
Parents
Observation
Physicians
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. / Lin, Tzou Yien; Wang, Ying Hsiang; Chang, Luan Yin; Chiu, Cheng Hsun; Huang, Yhu Chering; Tang, Haiwen; Bock, Hans L.

於: Chang Gung Medical Journal, 卷 26, 編號 5, 01.05.2003, p. 315-322.

研究成果: 雜誌貢獻文章

@article{a5355ba5feb6436a99c894c51f2c27c6,
title = "Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age",
abstract = "Background: Combined vaccines are urgently needed to ensure compliance with the increasing number of recommended vaccines for children. We evaluated the safety and antibody response to a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b (DTaP-IPV/Hib) combination vaccine administrated to infants at 2, 4, and 6 months of age. Methods: Sixty healthy infants between 6 and 12 weeks of age were enrolled. One group of vaccines received the DTaP-IPV/Hib in a single injection, while another group concurrently received DTaP-IPV and Hib at separate injection sites. Solicited adverse events were monitored by parental observation and were recorded on a diary card. Levels of serum antibodies to DTaP and polyribosyl-ribitolphosphate-tetanus (PRP-T) antigens were collected before the first vaccine dose and 1 month after the third vaccine dose. Results: The combined-injection group tended to have lower local reactions, and there was no increase in reactogenicity when compared with the separate-injection group. Seroconversion rates were 100{\%} in both groups for all antigens, except for the anti-polio 2 antibody in the combined-injection group (96.4{\%}). The combined-injection group had lower antibody levels of PRP (8.45 μg/ml) than did the separate-injection group (20.61 μg/ml). However, the percentage of vaccines achieving protective levels of antibody to PRP (≥ 0.15 μg/ml or ≥ 1.0 μg/ml) was similar in both groups. Conclusions: DTaP-IPV/Hib may be safely and effectively administered to healthy infants, using a 2-, 4-, and 6-month vaccination schedule. This combined vaccine is cost-effective, more acceptable to parents and physicians, and minimizes distress to infants.",
keywords = "And acellular pertussis, Diphtheria, Haemophilus influenzae type b, Immunogenicity, Inactivated poliovirus vaccine, Reactogenicity, Tetanus",
author = "Lin, {Tzou Yien} and Wang, {Ying Hsiang} and Chang, {Luan Yin} and Chiu, {Cheng Hsun} and Huang, {Yhu Chering} and Haiwen Tang and Bock, {Hans L.}",
year = "2003",
month = "5",
day = "1",
language = "English",
volume = "26",
pages = "315--322",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "5",

}

TY - JOUR

T1 - Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age

AU - Lin, Tzou Yien

AU - Wang, Ying Hsiang

AU - Chang, Luan Yin

AU - Chiu, Cheng Hsun

AU - Huang, Yhu Chering

AU - Tang, Haiwen

AU - Bock, Hans L.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: Combined vaccines are urgently needed to ensure compliance with the increasing number of recommended vaccines for children. We evaluated the safety and antibody response to a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b (DTaP-IPV/Hib) combination vaccine administrated to infants at 2, 4, and 6 months of age. Methods: Sixty healthy infants between 6 and 12 weeks of age were enrolled. One group of vaccines received the DTaP-IPV/Hib in a single injection, while another group concurrently received DTaP-IPV and Hib at separate injection sites. Solicited adverse events were monitored by parental observation and were recorded on a diary card. Levels of serum antibodies to DTaP and polyribosyl-ribitolphosphate-tetanus (PRP-T) antigens were collected before the first vaccine dose and 1 month after the third vaccine dose. Results: The combined-injection group tended to have lower local reactions, and there was no increase in reactogenicity when compared with the separate-injection group. Seroconversion rates were 100% in both groups for all antigens, except for the anti-polio 2 antibody in the combined-injection group (96.4%). The combined-injection group had lower antibody levels of PRP (8.45 μg/ml) than did the separate-injection group (20.61 μg/ml). However, the percentage of vaccines achieving protective levels of antibody to PRP (≥ 0.15 μg/ml or ≥ 1.0 μg/ml) was similar in both groups. Conclusions: DTaP-IPV/Hib may be safely and effectively administered to healthy infants, using a 2-, 4-, and 6-month vaccination schedule. This combined vaccine is cost-effective, more acceptable to parents and physicians, and minimizes distress to infants.

AB - Background: Combined vaccines are urgently needed to ensure compliance with the increasing number of recommended vaccines for children. We evaluated the safety and antibody response to a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type b (DTaP-IPV/Hib) combination vaccine administrated to infants at 2, 4, and 6 months of age. Methods: Sixty healthy infants between 6 and 12 weeks of age were enrolled. One group of vaccines received the DTaP-IPV/Hib in a single injection, while another group concurrently received DTaP-IPV and Hib at separate injection sites. Solicited adverse events were monitored by parental observation and were recorded on a diary card. Levels of serum antibodies to DTaP and polyribosyl-ribitolphosphate-tetanus (PRP-T) antigens were collected before the first vaccine dose and 1 month after the third vaccine dose. Results: The combined-injection group tended to have lower local reactions, and there was no increase in reactogenicity when compared with the separate-injection group. Seroconversion rates were 100% in both groups for all antigens, except for the anti-polio 2 antibody in the combined-injection group (96.4%). The combined-injection group had lower antibody levels of PRP (8.45 μg/ml) than did the separate-injection group (20.61 μg/ml). However, the percentage of vaccines achieving protective levels of antibody to PRP (≥ 0.15 μg/ml or ≥ 1.0 μg/ml) was similar in both groups. Conclusions: DTaP-IPV/Hib may be safely and effectively administered to healthy infants, using a 2-, 4-, and 6-month vaccination schedule. This combined vaccine is cost-effective, more acceptable to parents and physicians, and minimizes distress to infants.

KW - And acellular pertussis

KW - Diphtheria

KW - Haemophilus influenzae type b

KW - Immunogenicity

KW - Inactivated poliovirus vaccine

KW - Reactogenicity

KW - Tetanus

UR - http://www.scopus.com/inward/record.url?scp=0043235634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043235634&partnerID=8YFLogxK

M3 - Article

C2 - 12934847

AN - SCOPUS:0043235634

VL - 26

SP - 315

EP - 322

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 5

ER -